Market Cap 9.29B
Revenue (ttm) 634.44M
Net Income (ttm) -25.51M
EPS (ttm) N/A
PE Ratio 96.57
Forward PE 92.98
Profit Margin -4.02%
Debt to Equity Ratio 0.00
Volume 1,180,800
Avg Vol 893,566
Day's Range N/A - N/A
Shares Out 56.26M
Stochastic %K 85%
Beta 1.08
Analysts Strong Sell
Price Target $180.61

Company Profile

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale co...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 781 250 0111
Fax: 781 250 0115
Address:
Building 1, Suite 100 41 Seyon Street, Waltham, United States
Estimize
Estimize Oct. 16 at 11:03 AM
Wall St is expecting 0.42 EPS for $RGEN Q3 [Reporting 10/28 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co
0 · Reply
smartkarma
smartkarma Oct. 15 at 10:54 AM
$RGEN | Primer: Repligen Corp (RGEN US) - Oct 2025 "Repligen is a key player in the bioprocessing industry, providing critical technologies for the manufacturing of biologic drugs. The company has..." - αSK (Smartkarma) Read more: https://www.smartkarma.com/insights/primer-repligen-corp-rgen-us-oct-2025
0 · Reply
BOOGEYMAN_TRADEZ
BOOGEYMAN_TRADEZ Oct. 13 at 4:59 PM
$ATYR Some pretty stunning DD here for our $ATYR swing IMO.. (approx 40% short) maybe the next $SAVA bounce Director (Paul Schimmel) who just bought 1,000,000 shares of $ATYR at .90-.95 range also founded the following $RGEN up 1,356% all time $ALNY up 7,748% all time $ALKS up 539% all time $CBST bought for 8.4 billion by Merck Angiosyn bought by Pfizer in 2005
0 · Reply
SweepCastApp
SweepCastApp Oct. 4 at 5:36 AM
$RGEN: Unusual Options Activity Alerted CALL flow observed 35x contracts at Strike price of $150 Exp on 12/19/2025 with Premium of $32K and showing BULLISH Sentiment
0 · Reply
IN0V8
IN0V8 Oct. 3 at 4:50 PM
$RGEN Buy Barclays raises target price to $160 from $150
0 · Reply
Estimize
Estimize Oct. 2 at 11:00 AM
Wall St is expecting 0.41 EPS for $RGEN Q3 [Reporting 11/04 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co
0 · Reply
JarvisFlow
JarvisFlow Oct. 1 at 5:23 PM
HSBC updates rating for Repligen ( $RGEN ) to Buy, target set at 150.
0 · Reply
rooneyray
rooneyray Oct. 1 at 2:59 PM
$MXCT $RGEN $TWST $CLPT This entire sector is undervalued. Let's go gang.
0 · Reply
SweepCastApp
SweepCastApp Sep. 28 at 7:15 AM
$RGEN: Unusual Options Activity Alerted PUT flow observed 600x contracts at Strike price of $115 Exp on 06/18/2026 with Premium of $738K and showing BULLISH Sentiment
0 · Reply
SweepCastApp
SweepCastApp Sep. 26 at 3:02 PM
$RGEN: SWEEP CALL orders came through 25 @ 17, Strike 110.0, Exp 10/17/2025, Premium $42,500, Sentiment BEARISH
0 · Reply
Latest News on RGEN
Repligen to Report Third Quarter 2025 Financial Results

Oct 15, 2025, 7:30 AM EDT - 10 days ago

Repligen to Report Third Quarter 2025 Financial Results


mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 2 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX DHR GRAL ILMN IONS MRNA


Repligen Corporation: Still Navigating Through The Covid Cliff

Aug 14, 2025, 3:24 PM EDT - 2 months ago

Repligen Corporation: Still Navigating Through The Covid Cliff


Repligen Stock Outlook: Risk Skewed To The Downside Through 2026

Jul 31, 2025, 10:45 AM EDT - 3 months ago

Repligen Stock Outlook: Risk Skewed To The Downside Through 2026


Repligen Corporation (RGEN) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 5:31 PM EDT - 3 months ago

Repligen Corporation (RGEN) Q2 2025 Earnings Call Transcript


Repligen to Report Second Quarter 2025 Financial Results

Jul 17, 2025, 7:30 AM EDT - 3 months ago

Repligen to Report Second Quarter 2025 Financial Results


Repligen Corporation (RGEN) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 12:58 PM EDT - 6 months ago

Repligen Corporation (RGEN) Q1 2025 Earnings Call Transcript


Repligen Reports First Quarter 2025 Financial Results

Apr 29, 2025, 7:30 AM EDT - 6 months ago

Repligen Reports First Quarter 2025 Financial Results


Repligen: Ongoing Bioprocessing Market Recovery

Mar 20, 2025, 7:52 AM EDT - 7 months ago

Repligen: Ongoing Bioprocessing Market Recovery


Repligen Corporation (RGEN) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 2:53 PM EST - 8 months ago

Repligen Corporation (RGEN) Q4 2024 Earnings Call Transcript


Repligen Launches the CTech™ SoloVPE® PLUS System

Jan 6, 2025, 7:30 AM EST - 10 months ago

Repligen Launches the CTech™ SoloVPE® PLUS System


Repligen Corporation (RGEN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 3:07 PM EST - 1 year ago

Repligen Corporation (RGEN) Q3 2024 Earnings Call Transcript


Repligen Corporation (RGEN) Q2 2024 Earnings Call Transcript

Jul 30, 2024, 3:03 PM EDT - 1 year ago

Repligen Corporation (RGEN) Q2 2024 Earnings Call Transcript


Repligen Lowers Guidance On China Weakness, Analyst Expects

Jul 30, 2024, 12:01 PM EDT - 1 year ago

Repligen Lowers Guidance On China Weakness, Analyst Expects


Repligen Reports Second Quarter 2024 Financial Results

Jul 30, 2024, 7:30 AM EDT - 1 year ago

Repligen Reports Second Quarter 2024 Financial Results


Repligen to Report Second Quarter 2024 Financial Results

Jul 16, 2024, 7:30 AM EDT - 1 year ago

Repligen to Report Second Quarter 2024 Financial Results


Top 3 Health Care Stocks That Could Blast Off In June

Jun 21, 2024, 8:22 AM EDT - 1 year ago

Top 3 Health Care Stocks That Could Blast Off In June

ENOV PEN


Repligen Announces CEO Transition Plan

Jun 13, 2024, 7:00 AM EDT - 1 year ago

Repligen Announces CEO Transition Plan


Repligen Reports First Quarter 2024 Financial Results

May 1, 2024, 7:30 AM EDT - 1 year ago

Repligen Reports First Quarter 2024 Financial Results


Repligen to Report First Quarter 2024 Financial Results

Apr 17, 2024, 7:30 AM EDT - 1 year ago

Repligen to Report First Quarter 2024 Financial Results


Repligen Appoints Maggie A. Pax to Board of Directors

Mar 19, 2024, 7:30 AM EDT - 1 year ago

Repligen Appoints Maggie A. Pax to Board of Directors


Estimize
Estimize Oct. 16 at 11:03 AM
Wall St is expecting 0.42 EPS for $RGEN Q3 [Reporting 10/28 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co
0 · Reply
smartkarma
smartkarma Oct. 15 at 10:54 AM
$RGEN | Primer: Repligen Corp (RGEN US) - Oct 2025 "Repligen is a key player in the bioprocessing industry, providing critical technologies for the manufacturing of biologic drugs. The company has..." - αSK (Smartkarma) Read more: https://www.smartkarma.com/insights/primer-repligen-corp-rgen-us-oct-2025
0 · Reply
BOOGEYMAN_TRADEZ
BOOGEYMAN_TRADEZ Oct. 13 at 4:59 PM
$ATYR Some pretty stunning DD here for our $ATYR swing IMO.. (approx 40% short) maybe the next $SAVA bounce Director (Paul Schimmel) who just bought 1,000,000 shares of $ATYR at .90-.95 range also founded the following $RGEN up 1,356% all time $ALNY up 7,748% all time $ALKS up 539% all time $CBST bought for 8.4 billion by Merck Angiosyn bought by Pfizer in 2005
0 · Reply
SweepCastApp
SweepCastApp Oct. 4 at 5:36 AM
$RGEN: Unusual Options Activity Alerted CALL flow observed 35x contracts at Strike price of $150 Exp on 12/19/2025 with Premium of $32K and showing BULLISH Sentiment
0 · Reply
IN0V8
IN0V8 Oct. 3 at 4:50 PM
$RGEN Buy Barclays raises target price to $160 from $150
0 · Reply
Estimize
Estimize Oct. 2 at 11:00 AM
Wall St is expecting 0.41 EPS for $RGEN Q3 [Reporting 11/04 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co
0 · Reply
JarvisFlow
JarvisFlow Oct. 1 at 5:23 PM
HSBC updates rating for Repligen ( $RGEN ) to Buy, target set at 150.
0 · Reply
rooneyray
rooneyray Oct. 1 at 2:59 PM
$MXCT $RGEN $TWST $CLPT This entire sector is undervalued. Let's go gang.
0 · Reply
SweepCastApp
SweepCastApp Sep. 28 at 7:15 AM
$RGEN: Unusual Options Activity Alerted PUT flow observed 600x contracts at Strike price of $115 Exp on 06/18/2026 with Premium of $738K and showing BULLISH Sentiment
0 · Reply
SweepCastApp
SweepCastApp Sep. 26 at 3:02 PM
$RGEN: SWEEP CALL orders came through 25 @ 17, Strike 110.0, Exp 10/17/2025, Premium $42,500, Sentiment BEARISH
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 26 at 10:36 AM
Enter: $RGEN OCT 17 2025 $125 CALLS Buy in Price: $6.70 - $7.00 Take Profit: $8.71 Stop Bleeding: $5.90 ROI Potential: 30% Exit Within: 229 Minutes https://moneygroup.us/alerts
0 · Reply
shkspr
shkspr Sep. 23 at 3:49 PM
$RGEN This chart is bearish-biased with corrective rallies, defined by the EMA-100 acting as a dynamic lid. The 115–125 support is the only thing preventing a structural breakdown. A decisive weekly close above 146 would be the game-changer. Until then, the path of least resistance remains down. Trade Plan: Bulls: A weekly close above 146 would be the first legitimate signal of trend reversal. Only then can long positions target 170–180+ (old swing highs). Until then, rallies should be treated as corrective. Bears: As long as price stays under the EMA-100, bears remain favored. Best setups: fade rallies into 132–146 resistance, with stops above 150. Neutral stance: Sideways action between 115–135 is a chop zone, good for range trading but not for directional bets.
1 · Reply
surfmav
surfmav Sep. 22 at 10:35 PM
$GSK , $TEVA, $RGEN Just an FYI: $TEVA is selling Leucovorin today and it's available for doctors to prescribe via injection or tablets: https://www.tevausa.com/our-products/tevagenerics/teva-generics-catalog/vision-product-page/leucovorincalciumtabletsusp $GSK is applying to re-label Wellcovorin-Leucovorin as a treatment for cerebral folate deficiency (CFD): https://www.gsk.com/en-gb/media/press-releases/gsk-to-submit-label-update-for-wellcovorin-leucovorin-at-us-fda-s-request/ Both are up AH. Hope that helps someone here today. As always GLTA.
0 · Reply
stockstelegraph
stockstelegraph Sep. 22 at 3:38 PM
Top Analyst Upgrades (Sep 22) 🚀 $AMAT: PT $172$209 $SHOO: PT $25$40 $HP: PT $17$25 $RGEN: PT $130$155 $EAT: PT $165$175 🔼 All upgraded with bullish outlooks. 📊 Which one are you watching? #StockMarket #Upgrades #Investing #OptionsTrading #Premarket
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 19 at 8:31 PM
Enter: $RGEN OCT 17 2025 $120 CALLS Buy in Price: $5.07 - $7.80 Take Profit: $10.04 Stop Bleeding: $4.46 ROI Potential: 98% Exit Within: 129 Minutes https://moneygroup.us/alerts
0 · Reply
Estimize
Estimize Sep. 18 at 11:03 AM
Wall St is expecting 0.41 EPS for $RGEN Q3 [Reporting 11/04 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co
0 · Reply
c2rshi2r
c2rshi2r Sep. 17 at 10:33 PM
$RGEN this stock should be more than 130 … I am not sure what’s holding this down.
0 · Reply
RunnerSignals
RunnerSignals Sep. 16 at 8:52 PM
$PRME $CHGG $GPCR $VERX $RGEN opened in red, closed on FIRE!
0 · Reply
JarvisFlow
JarvisFlow Sep. 12 at 10:30 AM
Jefferies updates rating for Repligen ( $RGEN ) to Hold, target set at 145 → 135.
0 · Reply
Optionshmoptions
Optionshmoptions Sep. 9 at 2:19 PM
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 5 at 10:00 PM
$RGEN Really good write-up that perfectly summarizes RGEN's present situation. So if you want to bring your RGEN knowledge up to date or just discover RGEN, this is required reading. https://beyondspx.com/quote/RGEN/repligen-s-differentiated-technologies-power-bioprocessing-recovery-and-market-share-gains-nasdaq-rgen#analysis
0 · Reply
Estimize
Estimize Sep. 4 at 11:06 AM
Wall St is expecting 0.42 EPS for $RGEN Q3 [Reporting 11/04 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co
0 · Reply